By Market & Region

SHERIDAN, WYOMING – May 7, 2025 – Terumo Blood and Cell Technologies (Terumo BCT), a leading medical technology company, has announced the appointment of Patrick Daly as its new Chief Business Officer. Daly, a seasoned veteran with over 30 years of experience in the healthcare industry, will play a crucial role in driving business growth and enhancing Terumo BCT's strategic initiatives.

With a distinguished career in business development and strategic partnerships, Daly brings valuable expertise to the company as it continues to expand its portfolio of solutions for blood collection, therapeutic apheresis, and cell therapy. His leadership is expected to accelerate Terumo BCT's goals for innovation, market integration, and enterprise expansion.

SHERIDAN, WYOMING – May 7, 2025 – Intuitive (NASDAQ: ISRG), a global leader in robotic-assisted surgery, today announced the U.S. Food and Drug Administration (FDA) has granted clearance for its da Vinci Single Port (SP) surgical system for transanal local excision/resection. This clearance, which builds upon previous FDA approvals for transabdominal colorectal procedures, further enhances the capabilities of the da Vinci SP system, supporting minimally invasive surgery via natural orifice access.

Advancing Colorectal Surgery with Innovative Technology

The da Vinci SP system is designed to improve precision in surgeries that require access to narrow body cavities, such as those in the lower pelvis and rectum. By allowing surgeons to control up to three multi-jointed instruments and a high-definition articulating camera through a single entry point, the system offers enhanced freedom of movement in these smaller, more confined spaces.

SHERIDAN, WYOMING – May 7, 2025 – Intuitive (Nasdaq: ISRG), a global leader in minimally invasive care and robotic-assisted surgery, has announced its financial results for the first quarter of 2025, showcasing impressive growth and a strong strategic position in the healthcare technology market. The company's financial performance highlights robust growth in surgical procedures, system placements, and revenue, underscoring its leadership in the evolving field of robotic-assisted surgery.

Robust Growth in da Vinci Procedures and System Placements

In Q1 2025, Intuitive saw a 17% year-over-year increase in worldwide da Vinci procedures, reflecting the growing adoption of its robotic surgery systems. This increase is part of a broader trend towards minimally invasive surgery, where precision, reduced recovery times, and improved patient outcomes are driving demand.

SHERIDAN, WYOMING – May 7, 2025 – Intuitive, a global leader in minimally invasive care and the pioneer of robotic-assisted surgery (RAS), has published two groundbreaking studies highlighting the critical role of RAS in expanding access to high-quality care. These findings emphasize how robotic-assisted procedures contribute to improving patient outcomes, especially in medical deserts, and ultimately aid the growth of minimally invasive surgery (MIS), benefiting patients globally.

SHERIDAN, WYOMING – May 7, 2025 – Intuitive, a global leader in minimally invasive care and robotic-assisted surgery, has announced that its SureForm 45 stapler has received FDA clearance for use with the da Vinci SP surgical system. The stapler is now approved for thoracic, colorectal, and urology procedures, marking a significant milestone in robotic surgical technology.

This advancement allows surgeons to use the SureForm 45 stapler in single-port robotic surgeries, providing enhanced control and improved procedural efficiency. The FDA's clearance represents a major leap forward for Intuitive's continued innovation in surgical robotics and its commitment to reducing patient recovery times and enhancing surgical outcomes.

SHERIDAN, WYOMING – May 7, 2025 – Resmed (NYSE: RMD, ASX: RMD), a leading health technology company specializing in sleep, breathing, and home care, has announced the acquisition of VirtuOx, a prominent independent diagnostic testing facility (IDTF) focused on sleep, respiratory, and cardiac conditions. This strategic acquisition strengthens Resmed’s position in virtual care and reinforces its commitment to improving healthcare delivery by providing more accessible and coordinated care to patients and healthcare providers.

SHERIDAN, WYOMING – May 7, 2025 – Resmed Inc. (NYSE: RMD, ASX: RMD), a global leader in connected health solutions for sleep and respiratory care, has announced impressive third-quarter fiscal 2025 results. The company achieved a substantial year-over-year revenue growth of 8%, underscoring the continued demand for its innovative products and digital health solutions. With a focus on operational excellence and expanding its global footprint, Resmed has delivered a strong performance, further solidifying its position as a market leader in the healthcare sector.

SHERIDAN, WYOMING – May 7, 2025 – Resmed (NYSE: RMD, ASX: RMD), a global leader in health technology focused on sleep, breathing, and home care, has announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. Schwartz brings over two decades of experience in leading investor engagement strategies at some of the world's leading health technology and financial services organizations. Her extensive background will be instrumental in advancing Resmed’s long-term strategic goals.

SHERIDAN, WYOMING – May 7, 2025 – Hologic, Inc. (Nasdaq: HOLX), a leader in medical technologies focused on women’s health, today announced its financial results for the second quarter of fiscal 2025. The company reported revenue of $1,005.3 million, slightly surpassing the upper end of its guidance, despite a decline in overall earnings per share (EPS) due to non-cash impairment charges. Hologic’s performance was primarily driven by strong demand in its diagnostics and skeletal businesses, along with ongoing profitability improvements and strategic share buybacks.

SHERIDAN, WYOMING – May 7, 2025 – Hologic, Inc. (Nasdaq: HOLX) is set to showcase its latest innovations in AI-driven mammography technology at the Society of Breast Imaging (SBI) Annual Symposium in Colorado Springs this week. A key highlight of the event will be the presentation of a pioneering study conducted at Massachusetts General Hospital, demonstrating the impact of Hologic's Genius AI® Detection Solution in improving breast cancer detection.

Revolutionary AI Mammography Technology

At the core of Hologic's presentation is a retrospective study involving 5,000 digital breast tomosynthesis (3D mammography) exams conducted between 2016 and 2019. This study focused on evaluating the performance of the Genius AI® Detection 2.0 mammography solution. Researchers analyzed screening results to determine the AI system’s ability to identify previously missed cancers and accurately detect and localize confirmed cases.

SHERIDAN, WYOMING – May 7, 2025 – Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health technologies, has unveiled its 2024 annual sustainability report, highlighting the company's robust environmental, social, and governance (ESG) initiatives. This year’s report places a strong emphasis on the company’s increased environmental commitments and its ongoing efforts to promote access and equity in women’s health.

The report showcases Hologic’s continued focus on enhancing global healthcare for women, with its groundbreaking technologies impacting over 193 million lives in 2024 alone. The company has committed to pushing boundaries in both health and sustainability, driving substantial improvements in women's healthcare and reducing its environmental footprint.

Expanding Access and Equity in Women’s Health

SHERIDAN, WYOMING – May 7, 2025 – Olympus Corporation has announced key changes to its leadership structure, including the appointment of Bob White as a new Representative Executive Officer, President, and Chief Executive Officer, effective June 1, 2025. The company also revealed a change in the responsibilities of Yasuo Takeuchi, who will continue in his roles as Director, Representative Executive Officer, Executive Chairperson, and ESG Officer. These changes come as part of Olympus’s ongoing efforts to drive its transformation and growth in the global MedTech sector.

SHERIDAN, WYOMING – May 7, 2025 – Olympus Corporation, a global MedTech leader, has announced its most successful "Dress in Blue" campaign yet, marking a new milestone in its commitment to Colorectal Cancer Awareness Month. With 6,810 employees from across the globe participating, this year’s campaign underscores Olympus’ ongoing dedication to reducing cancer-related deaths through awareness and early detection initiatives.

Record Participation in Global Campaign

This year, Olympus achieved an all-time high participation rate in the company-wide campaign, with employees joining from various regions, including Japan, the Americas, EMEA (Europe, Middle East, and Africa), APAC (Asia-Pacific), and China. For the third consecutive year, the "Dress in Blue" campaign encouraged Olympus employees to wear blue, the color of colorectal cancer awareness, as a show of solidarity and support for the cause.

SHERIDAN, WYOMING – May 7, 2025 – Baxter International Inc. (NYSE:BAX), a global leader in medical technologies, has announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per share of common stock. This dividend is payable on July 1, 2025, to shareholders of record as of May 30, 2025. The indicated annual dividend rate is set at $0.68 per share.

Strategic Commitment to Shareholders

As part of its ongoing commitment to delivering value to its shareholders, Baxter continues to maintain a strong dividend policy. The company’s decision to declare this quarterly cash dividend reflects both the stability of its financial performance and its dedication to providing consistent returns to its investors.

SHERIDAN, WYOMING – May 7, 2025 – Baxter International Inc. (NYSE: BAX), a leading global medtech company, has announced its first-quarter financial results for 2025, reflecting solid performance driven by strategic transformation initiatives. The company’s results indicate continued growth across its core business segments, positioning Baxter for long-term value creation despite global macroeconomic uncertainty.

Strategic Transformation and Focus on Execution

"Our solid performance in the first quarter of 2025 reflects the ongoing impact of our transformation journey," said Brent Shafer, chair and interim CEO of Baxter. "Baxter today is a more focused and agile organization, well-positioned to drive enhanced value for patients, healthcare providers, customers, and shareholders through our reinvigorated emphasis on execution, innovation, and profitable growth."

SHERIDAN, WYOMING – May 7, 2025 – Baxter International Inc. (NYSE: BAX), a global leader in medical technology, will host a conference call on Thursday, May 8, 2025, at 7:30 a.m. Central Time to discuss its first-quarter 2025 financial results. Investors, analysts, and other stakeholders are invited to participate in the call by pre-registering through the provided link to receive the necessary call-in information.

SHERIDAN, WYOMING – May 7, 2025 – Baxter International Inc., a global leader in advancing surgical innovation, has announced the launch of its Hemopatch Sealing Hemostat with room temperature storage at a symposium in Vienna, Austria. This new product evolution significantly improves accessibility for surgeons, offering a practical and effective solution for controlling bleeding and preventing leakage during surgery. The product is now available for order throughout Europe, marking a key step forward in Baxter’s ongoing commitment to enhancing patient care.

SHERIDAN, WYOMING – May 7, 2025 – Edwards Lifesciences (NYSE: EW), a global leader in structural heart innovation, will announce its operating results for the first quarter ending March 31, 2025, after market close on Wednesday, April 23, 2025. The company will then host a conference call at 5:00 p.m. ET that same day to discuss these results in detail, providing insights into its financial performance and future strategic direction.

Conference Call Details and Participation

Edwards Lifesciences invites all interested parties to join the conference call. To participate, dial (877) 704-2848 or (201) 389-0893. For those unable to attend live, the conference call will be available for replay on the "Investor Relations" section of the Edwards website at ir.edwards.com.

About Edwards Lifesciences

SHERIDAN, WYOMING – May 7, 2025 – Edwards Lifesciences (NYSE: EW) today unveiled new eight-year clinical data, confirming the exceptional long-term performance of its RESILIA tissue technology in aortic surgical valves. The data demonstrate significant improvements in patient outcomes, reinforcing the company's leadership in structural heart solutions.

The new findings, presented at the Heart Valve Society Annual Meeting, provide compelling evidence that patients receiving aortic surgical valves with RESILIA tissue experienced significantly better long-term outcomes compared to those with non-RESILIA tissue valves. These results highlight the value of Edwards’ innovation in delivering superior durability and performance, crucial for improving patient care and reducing the need for reoperations.

SHERIDAN, WYOMING – May 7, 2025 – Edwards Lifesciences (NYSE: EW), a global leader in structural heart innovation, has announced its financial results for the first quarter ended March 31, 2025. The company delivered impressive growth across key product categories, including Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT), positioning itself for continued success in the structural heart market.

Strong Sales Growth Drives First Quarter Results

In Q1 2025, Edwards Lifesciences reported total sales of $1.41 billion, reflecting a robust 6.2% increase year-over-year, or 7.9% on an adjusted basis. The company also posted a solid earnings per share (EPS) of $0.622, with adjusted EPS of $0.64, reinforcing its strong financial position.